Schott Pharma stock gains as revenue rises 9.87 percent

Published on 09/22/2026 at 14:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Schott Pharma stock reached EUR 23.65 on September 22, 2026, 0.85 percent below its yearly high. Quarterly revenue rose 9.87 percent to EUR 281.76 million.

Pharma-Glasfläschchen auf Fließband in moderner Produktionsanlage — SCHOTT Pharma (DE000A3ENQ51) zeigt Glasfläschchen für Medikamente auf modernem Fließband in moderner sauberer Reinraumfertigungsanlage, Illustration mit AI erstellt.

Schott Pharma stock (ISIN DE000A3ENQ51) reached EUR 23.65 on Xetra at 9:28 a.m. on September 22, 2026, up 0.6 percent from the previous close. The price remained close to the 52-week high of EUR 23.85 set on September 15, 2026, while the 52-week low stood at EUR 12.62 on March 23, 2026.

Revenue rises in latest quarter

The latest reported quarter delivered revenue of EUR 281.76 million on August 12, 2026, compared with EUR 256.46 million in the year-earlier quarter. That represents growth of 9.87 percent, while earnings per share declined to EUR 0.26 from EUR 0.30 in the same comparison period, according to finanzen.ch.

The figures show a clear split in the quarter: sales expanded by EUR 25.30 million year over year, but quarterly EPS fell by EUR 0.04. For investors, the revenue trajectory is therefore stronger than the earnings progression in the period reported on August 12, 2026.

Stock remains near yearly high

The Xetra quotation was EUR 0.20 below the 52-week high at the September 22, 2026 morning snapshot, equivalent to a gap of 0.85 percent. At EUR 23.65, the stock was EUR 11.03 above its 52-week low, showing how sharply the trading range widened between March and September 2026.

Market capitalization was listed at EUR 3.47 billion in the TradingView market snapshot, while the company reported 27.23 million shares outstanding and fiscal-year revenue of EUR 986.21 million. The same snapshot lists fiscal-year net income of EUR 146.45 million, giving investors a dated reference point for the company scale alongside the latest quarterly revenue figure.

Next report date is December 10

The next scheduled reporting date is December 10, 2026, for fourth-quarter 2026 figures. The available estimate for that quarter is EPS of EUR 0.31 and revenue of EUR 274.77 million, according to TradingView.

That estimate would place projected quarterly revenue EUR 6.99 million below the EUR 281.76 million reported for the latest quarter, while projected EPS would be EUR 0.05 above the latest reported EUR 0.26. The contrast makes the December reporting date the next concrete checkpoint for the balance between sales growth and per-share earnings.

Schott Pharma stock stays above EUR 23

Schott Pharma stock stood at EUR 23.65 on Xetra at 9:28 a.m. on September 22, 2026, with 1,701 shares traded in the reported morning session. The price was 0.6 percent higher than the previous close and 0.85 percent below the September 15 yearly high.